Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine.
PCSK9 is a natural inhibitor of LDL receptor (LDLR) that binds the extracellular domain of LDLR and triggers its intracellular degradation. PCSK9 and LDLR are coordinately regulated at the transcriptional level by sterols through their promoter-imbedded sterol response elements (SRE) and co-induced by statins. Identification of regulatory networks modulating PCSK9 transcription is important for developing selective repressors of PCSK9 to improve statin efficacy by prolonging the up-regulation of LDLR. Interestingly, the plant-derived hypocholesterolemic compound berberine (BBR) up-regulates LDLR expression while down-regulating PCSK9. In our investigations to define mechanisms underlying the transcriptional suppression of PCSK9 by BBR in HepG2 cells, we have identified a highly conserved hepatocyte nuclear factor 1 (HNF1) binding site residing 28 bp upstream from SRE as a critical sequence motif for PCSK9 transcription and its regulation by BBR. Mutation of the HNF1 site reduced PCSK9 promoter activity >90%. A battery of functional assays identified HNF1alpha as the predominant trans-activator for PCSK9 gene working through this sequence motif. We further provide evidence suggesting that HNF1 site works cooperatively with SRE as HNF1 mutation significantly attenuated the activity of nuclear SREBP2 to transactivate PCSK9 promoter. Finally, we show that a coordinate modest reduction of HNF1alpha and nuclear SREBP2 by BBR led to a strong suppression of PCSK9 transcription through these two critical regulatory sequences. This is the first described example of SREBP pairing with HNF1 to control an important regulatory pathway in cholesterol homeostasis. This work also provides a mechanism for how BBR suppresses PCSK9 transcription.
Li
Hai
H
Department of Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304, USA.
Dong
Bin
B
Park
Sahng Wook
SW
Lee
Hyun-Sook
HS
Chen
Wei
W
Liu
Jingwen
J
D000924:Anticholesteremic Agents / Q000494:pharmacology*; D001483:Base Sequence; D001599:Berberine / Q000494:pharmacology*; D001665:Binding Sites; D045744:Cell Line, Tumor; D005786:Gene Expression Regulation; D051538:Hepatocyte Nuclear Factor 1-alpha / Q000378:metabolism*; D006801:Humans; D008969:Molecular Sequence Data; D009154:Mutation; D011401:Promoter Regions, Genetic; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D034741:RNA, Small Interfering / Q000378:metabolism; D011973:Receptors, LDL / Q000378:metabolism; D012689:Sequence Homology, Nucleic Acid; D012697:Serine Endopeptidases / Q000378:metabolism*; D014158:Transcription, Genetic
D000924:Anticholesteremic Agents; D051538:Hepatocyte Nuclear Factor 1-alpha; D034741:RNA, Small Interfering; D011973:Receptors, LDL; D001599:Berberine; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases
Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5374-9
15805190
Nat Genet. 2005 Feb;37(2):161-5
15654334
Proc Natl Acad Sci U S A. 2004 May 4;101(18):7100-5
15118091
Hum Genet. 2004 Mar;114(4):349-53
14727179
Gen Comp Endocrinol. 2008 Jan 15;155(2):359-67
17686483
Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12027-32
14512514
J Biol Chem. 2004 Nov 19;279(47):48865-75
15358785
J Biol Chem. 2009 Apr 17;284(16):10561-70
19224862
Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11915-20
18695239
FEBS Lett. 2008 Mar 19;582(6):949-55
18298956
Am J Physiol Gastrointest Liver Physiol. 2006 Mar;290(3):G466-75
16223942
Endocr Metab Immune Disord Drug Targets. 2008 Dec;8(4):238-43
19075777
Nat Genet. 2008 Feb;40(2):161-9
18193043
J Biol Chem. 2004 Nov 26;279(48):50630-8
15385538
Toxicol Appl Pharmacol. 2009 Feb 1;234(3):281-92
19010343
J Biol Chem. 2000 Feb 18;275(7):4726-33
10671504
Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2170-6
16100034
Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1454-9
15178557
Genes Dev. 1991 Jun;5(6):1042-56
2044952
Mol Cell Biol. 2009 Jun;29(11):2945-59
19289501
J Biol Chem. 1995 Jan 20;270(3):1161-9
7836375
J Lipid Res. 2006 Oct;47(10):2134-47
16885565
Nat Med. 2004 Dec;10(12):1344-51
15531889
J Biol Chem. 2008 Apr 11;283(15):9666-73
18245819
Nat Genet. 2003 Jun;34(2):154-6
12730697
Metabolism. 2009 Jan;58(1):109-19
19059538
Trends Biochem Sci. 2007 Feb;32(2):71-7
17215125
J Lipid Res. 2009 May;50(5):820-31
19141871
J Lipid Res. 2008 Feb;49(2):399-409
17921436
Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11041-8
10500120
J Lipid Res. 2008 Feb;49(2):394-8
18033751
Clin Genet. 2004 May;65(5):419-22
15099351
Cell. 1997 May 2;89(3):331-40
9150132
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):928-33
12552133
Cell Metab. 2005 May;1(5):290-2
16054075
Science. 2004 Feb 27;303(5662):1378-81
14988562
J Lipid Res. 2007 Jul;48(7):1488-98
17449864
J Clin Invest. 2002 May;109(9):1125-31
11994399
J Biol Chem. 2006 Mar 10;281(10):6211-8
16407292
Atherosclerosis. 2008 Dec;201(2):266-73
18355829
J Biol Chem. 2007 Jun 22;282(25):18602-18612
17452316
EMBO J. 1991 Jun;10(6):1445-57
1673926
Expert Opin Ther Targets. 2009 Jan;13(1):19-28
19063703
Nat Genet. 2008 Feb;40(2):189-97
18193044
J Lipid Res. 2003 Nov;44(11):2109-19
12897189
J Lipid Res. 2007 Apr;48(4):763-7
17242417